Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 10/20 | 0.44 |
| ▸ | KCNJ1 | P48048 | 4/20 | 0.44 |
| ▸ | IDO1 | P14902 | 2/20 | 0.44 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL88304 | 0.87 | TSHR (0.55) | TSHRKCNH2KCNJ1IDO1LOXL2 | |
| SCHEMBL6141206 | 0.84 | IDO1 (0.54) | TSHRIDO1LOXL2AKR1C3 | |
| SCHEMBL3656180 | 0.83 | TSHR (0.62) | TSHRKCNH2KCNJ1IDO1LOXL2 | |
| SCHEMBL5546765 | 0.81 | TSHR (0.51) | TSHRKCNH2KCNJ1IDO1LOXL2 | |
| SCHEMBL28647542 | 0.80 | ALDH1A1 (0.49) | KCNH2HRH3 | |
| SCHEMBL5535044 | 0.79 | TSHR (0.50) | TSHRKCNH2KCNJ1IDO1LOXL2 | |
| SCHEMBL4586246 | 0.78 | TSHR (0.56) | TSHRKCNH2KCNJ1IDO1LOXL2 | |
| SCHEMBL67263 | 0.78 | TSHR (0.49) | TSHRKCNH2KCNJ1IDO1LOXL2 | |
| SCHEMBL5542239 | 0.78 | KCNH2 (0.49) | TSHRKCNH2KCNJ1IDO1LOXL2 | |
| SCHEMBL5535027 | 0.78 | KCNH2 (0.49) | TSHRKCNH2KCNJ1IDO1LOXL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 236 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037414-B2 | Processes for preparing pharmaceutically relevant peptides | STEALTH BIOTHERAPEUTICS INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-20240158400-A1 | SYNTHESIS OF A BRUTON'S TYROSINE KINASE INHIBITOR | PHARMACYCLICS LLC (US) | 2024-05-16 | — | — | US | disclosed |
| US-20240108740-A1 | THERAPEUTIC COMPOSITIONS INCLUDING SPN10 AND USES THEREOF | STEALTH BIOTHERAPEUTICS INC. (US) | 2024-04-04 | — | — | US | disclosed |
| US-11548913-B2 | Therapeutic compositions including peptides and uses thereof | STEALTH BIOTHERAPEUTICS INC. (US) | 2023-01-10 | — | — | US | disclosed |
| EP-3087093-B1 | PHARMACEUTICALLY RELEVANT AROMATIC-CATIONIC PEPTIDES | STEALTH BIOTHERAPEUTICS CORP (MC) | 2021-11-10 | — | — | EP | disclosed |
| US-11141456-B2 | Therapeutic compositions including frataxin, lactoferrin, and mitochondrial energy generating enzymes, and uses thereof | STEALTH BIOTHERAPEUTICS CORP (MC) | 2021-10-12 | — | — | US | disclosed |
| US-20210206803-A1 | THERAPEUTIC COMPOSITIONS INCLUDING PEPTIDES AND USES THEREOF | STEALTH BIOTHERAPEUTICS INC. | 2021-07-08 | — | — | US | disclosed |
| EP-3800192-A1 | PROCESSES FOR PREPARING PHARMACEUTICALLY RELEVANT PEPTIDES | Stealth Biotherapeutics Corp (MC) | 2021-04-07 | — | — | EP | disclosed |
| CN-112457368-A | Pharmaceutically-related aromatic-cationic peptides | 康德生物医疗技术公司 | 2021-03-09 | — | — | CN | disclosed |
| CN-106132984-B | Pharmaceutically-related aromatic-cationic peptides | 康德生物医疗技术公司 | 2020-12-08 | — | — | CN | disclosed |
| US-20020115863-A1 | Novel succinate compounds, compositions and methods of use and preparation | VICURON HOLDINGS LLC | 2002-08-22 | — | — | US | disclosed |
| EP-1185493-A1 | QUINONES FOR TREATMENT OF DISEASES | SLIL Biomedical Corporation (US) | 2002-03-13 | — | — | EP | disclosed |
| WO-2002010142-A1 | CYCLIC POLYAMINE COMPOUNDS FOR CANCER THERAPY | SLIL BIOMEDICAL CORPORATION (US) | 2002-02-07 | — | — | WO | disclosed |
| US-20010053555-A1 | METHODS FOR SOLID-PHASE SYNTHESIS OF HYDROXYLAMINE COMPOUNDS AND DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF | VERSICOR, INC. | 2001-12-20 | — | — | US | disclosed |
| US-6281245-B1 | ADMINISTERING DEFORMYLASE INHIBITOR | VERSICOR, INC. | 2001-08-28 | — | — | US | disclosed |
| WO-2001044178-A1 | NOVEL UREA COMPOUNDS, COMPOSITIONS AND METHODS OF USE AND PREPARATION | VERSICOR, INC. (US) | 2001-06-21 | — | — | WO | disclosed |
| WO-2001044179-A1 | NOVEL SUCCINATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE AND PREPARATION | VERSICOR, INC. (US) | 2001-06-21 | — | — | WO | disclosed |
| WO-2000066528-A2 | QUINONES FOR TREATMENT OF DISEASES | SLIL BIOMEDICAL CORPORATION (US) | 2000-11-09 | — | — | WO | disclosed |
| WO-1999057097-A2 | METHODS FOR SOLID-PHASE SYNTHESIS OF HYDROXYLAMINE COMPOUNDS AND DERIVATIVES, AND COMBINATORIAL LIBRARIES THEREOF | VERSICOR, INC. (US) | 1999-11-11 | — | — | WO | disclosed |
| WO-1998018754-A1 | METHODS FOR SOLID-PHASE SYNTHESIS OF HYDROXYLAMINE COMPOUNDS AND DERIVATIVES, AND COMBINATORIAL LIBRARIES THEREOF | VERSICOR, INC. (US) | 1998-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11141456-B2 | Therapeutic compositions including frataxin, lactoferrin, and mitochondrial energy generating enzymes, and uses thereof | ARG2, ABAT, FH | TSHR 2468/4885KCNH2 4480/4885KCNJ1 4114/4885 |
| US-12037414-B2 | Processes for preparing pharmaceutically relevant peptides | ADM2, VIP, PEPD | TSHR 1572/4885KCNH2 3274/4885KCNJ1 3829/4885 |
| US-20240158400-A1 | SYNTHESIS OF A BRUTON'S TYROSINE KINASE INHIBITOR | BTK, ABL1, LYN | TSHR 2081/4885KCNH2 3009/4885KCNJ1 3723/4885 |
| US-11548913-B2 | Therapeutic compositions including peptides and uses thereof | VIP, IAPP, TNNI3 | TSHR 2994/4885KCNH2 4202/4885KCNJ1 4349/4885 |
| US-20020115863-A1 | Novel succinate compounds, compositions and methods of use and preparation | PDF, MMP2, SDHA | TSHR 4589/4885KCNH2 4789/4885KCNJ1 4527/4885 |
| US-20210206803-A1 | THERAPEUTIC COMPOSITIONS INCLUDING PEPTIDES AND USES THEREOF | VIP, IAPP, TNNI3 | TSHR 2994/4885KCNH2 4202/4885KCNJ1 4349/4885 |
| US-20240108740-A1 | THERAPEUTIC COMPOSITIONS INCLUDING SPN10 AND USES THEREOF | S100A10, SPG11, TMSB10 | TSHR 3820/4885KCNH2 4430/4885KCNJ1 4019/4885 |
| US-20010053555-A1 | METHODS FOR SOLID-PHASE SYNTHESIS OF HYDROXYLAMINE COMPOUNDS AND DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF | HNMT, HAAO, HPSE | TSHR 1868/4885KCNH2 3937/4885KCNJ1 4482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.